Polypoidal Choroidal Vasculopathy

Evaluating Aflibercept With Reduced-Fluence Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: Insights from Longitudinal OCT Angiography

By MedXY 10/09/2026

This randomized trial compares aflibercept monotherapy versus combined with reduced-fluence photodynamic therapy for PCV, highlighting OCTA metrics that predict polypoidal lesion closure and treatment response over 52 weeks.

Clinical Updates news Ophthalmology

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review

By MedXY 09/22/2026

This review synthesizes evidence on PRN aflibercept treatment after complete polypoidal regression in PCV, highlighting recurrence rates, visual outcomes, and potential OCT biomarkers guiding individualized management.

news Ophthalmology

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD

By MedXY 05/27/2026

This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.

news Ophthalmology

High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy

By MedXY 12/24/2025

This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment intervals and reduced injection burden.